P160050/S012: Barricaid Annular Closure Device
FDA’s recorded scope: approval for an alternate manufacturing process and new supplier affecting critical components of the Barricaid implant device/delivery system, specifically the 8mm Delivery Sheath
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 3 FDA records to the applicant name Intrinsic Therapeutics. 1 entry is a PMA supplement. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 9, 2025 to Mar 24, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QES appears in 3 of the 3 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P160050, with 3 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 30 Commerce Way, Woburn, MA, 01801. Recorded on P160050/S012, decision dated Mar 24, 2026.
FDA’s recorded scope: approval for an alternate manufacturing process and new supplier affecting critical components of the Barricaid implant device/delivery system, specifically the 8mm Delivery Sheath
FDA’s recorded scope: approval for manufacturing process changes to the delivery instrument of the Barricaid Annular Closure Device
FDA’s recorded scope: approval for a new 6mm baseplate sized implant.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.